Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are ...
In life sciences manufacturing, inspections by the FDA, state regulators or other agencies are part of the job. But too often ...
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing ...
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC ...
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis ...
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging ...
The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...
I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast.
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...
A renewal of the FDA’s pediatric rare disease voucher program is couched within a massive $1.2 trillion spending bill the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results